Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 201–300 of 1,002
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 134
“In recent years, immune checkpoint inhibitors (ICIs) have achieved gratifying effects in a wide variety of tumors, including melanoma [1], renal cell carcinoma [2] and non-small cell lung cancer (NSCLC) [3], which greatly changed the traditional tumor treatment strategy and brought more survival benefits to patients […”
BackgroundCombinatorial therapy in tumor microenvironment: Where do we stand?
Kumari, S., Advani, D., Sharma, S., Ambasta, R. K., & Kumar, P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188585 · Cited by 130
Masini, C., Iotti, C., Giorgi, U. D., Bellia, S. R., Buti, S., Salaroli, F., Zampiva, I., Mazzarotto, R., Mucciarini, C., Vitale, M. G., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.09.016 · Cited by 122
Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Motzer, R. J., Choueiri, T. K., McDermott, D. F., Powles, T. B., Vano, Y. A., Gupta, S. K., Yao, J., Han, G. C., Ammar, R., Papillon‐Cavanagh, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004316 · Cited by 123
Self-citationNew rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
Rassy, E., Parent, P., Lefort, F., Boussios, S., Baciarello, G., & Pavlidis, N. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102882 · Cited by 124
Klümper, N., Ralser, D. J., Bawden, E., Landsberg, J., Zarbl, R., Kristiansen, G., Toma, M. I., Ritter, M., Hölzel, M., Ellinger, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000552 · Cited by 124
Bhatt, R. S., Berjis, A., Konge, J. C., Mahoney, K. M., Klee, A. N., Freeman, S. S., Chen, C.-H., Jegede, O. A., Catalano, P. J., Pignon, J., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0315 · Cited by 125
Kurtz, J., Pujade-Lauraine, É., Oaknin, A., Belin, L., Leitner, K., Cibula, D., Denys, H. G., Rosengarten, O. S., Rodrigues, M. J., de Gregorio, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00529 · Cited by 116
“Autoimmune disorder (any grade) 91 (22) 23 (11) Hypothyroidism 45 (11) 10 (5) Hyperthyroidism 8 (2) 5 (2) Hepatitis or transaminitis 9 (2) 1 (<1) Colitis or severe diarrhea 4 (1) 4 (2) Ocular 4 (1) 0 Pancreatitis 1 (<1) 0 Pneumonitis 3 (1) 0 Diabetes mellitus 2 (<1) 0 Adrenal insufficiency 2 (<1) 0 Nephritis 1 (<1) 0…”
Clinical Insights Into Novel Immune Checkpoint Inhibitors
Lee, J. B., Ha, S.-J., & Kim, H. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681320 · Cited by 112
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 124
“3% for the combination group and sunitinib group, respectively, and the combination treatment group reduced the risk of death by 47% (65).”
BackgroundNext-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 127
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 122
“positive and negative subgroups as well as across any risk category, without significant increase in toxicities [132].”
BackgroundImmune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 124
McGregor, B. A., Campbell, M. T., Xie, W., Farah, S., Bilen, M. A., Schmidt, A. L., Sonpavde, G., Kilbridge, K. L., Choudhury, A. D., Mortazavi, A., et al. (2020) · Cancer · doi:10.1002/cncr.33328 · Cited by 123
“Cohort 2: adrenal tumors (n = 18) 1 8 9 6 (1-20)”
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 131
Zhao, L., Liu, Y., Zhang, S., Wei, L., Cheng, H., Wang, J., & Wang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04821-w · Cited by 124
“For example, in the KEYNOTE-426 trial, when combined with pembrolizumab and vascular endothelial growth factor receptor (VEGFR) inhibitor axitinib, compared with monotherapy for primary advanced/metastatic renal cell carcinoma (mRCC), it improved progression-free survival (PFS) and overall survival (OS) in mRCC patien…”
BackgroundThe Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma
Monjarás-Ávila, C. U., Lorenzo‐Leal, A. C., Luque-Badillo, A. C., D’Costa, N. M., Chavez-Munoz, C. I., & Bach, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097946 · Cited by 128
“pies with immune checkpoin inhibitors may improve patient outcomes (Figure 3) [25,77].”
BackgroundEbrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03086-4 · Cited by 109
“5 and 6).”
Sahebjam, S., Forsyth, P. A., Tran, N., Arrington, J. A., Macaulay, R. J. B., Etame, A. B., Walko, C. M., Boyle, T. A., Peguero, E. N., Jaglal, M. V., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa260 · Cited by 115
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 117
Powles, T. B., Burotto, M., Escudier, B. J., Apolo, A. B., Bourlon, M. T., Shah, A. Y., Suárez, C., Porta, C., Barrios, C. H., Richardet, M. E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102994 · Cited by 108
Self-citationImmunotherapy: an alternative promising therapeutic approach against cancers
Gupta, S. L., Basu, S., Soni, V., & Jaiswal, R. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07525-8 · Cited by 115
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Marletta, S., Fusco, N., Munari, E., Luchini, C., Cimadamore, A., Brunelli, M., Querzoli, G., Martini, M., Vigliar, E., Colombari, R., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071073 · Cited by 124
“This restriction was issued in 2018 based on prelimina y results from Keynote-361 and IMvigor130 trials t at howed a r uced PFS with Keytruda and Tecentriq compared with c emothera y in patients with locally a vanced or metastatic UC who had not received prior therapy and whose tumors had low expressions of PD-L1.”
BackgroundInfluentialLisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 115
New emerging targets in cancer immunotherapy: the role of TIM3
Friedlaender, A., Addeo, A., & Banna, G. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000497 · Cited by 102
“More recently, adding ICI to targeted therapy has shown improved survival in renal cell carcinoma.(16) All of these strategies have shown the potential of combining treatments.”
BackgroundTargeting angiogenesis for liver cancer: Past, present, and future
Zhu, X., Tang, Z., & Sun, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.03.010 · Cited by 111
Lipid metabolism reprogramming in renal cell carcinoma
Heravi, G., Yazdanpanah, O., Podgorski, I., Matherly, L. H., & Liu, W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09996-w · Cited by 125
CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation
Beckermann, K. E., Hongo, R. A., Ye, X., Young, K. L., Carbonell, K., Contreras, D. C., Siska, P. J., Barone, S. M., Roe, C. E., Smith, C. C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138729 · Cited by 109
“While RCC can respond to PD-1 and CTLA4 checkpoint blockade immunotherapy, only a portion of patients achieve partial responses, and a smaller fraction generates durable responses (27–29).”
Tyrosine Kinase Receptors in Oncology
Esteban-Villarrubia, J., Castillo, J. J. S., Pozas, J., Román, M. S., Orejana, I., Torres-Jiménez, J., Carrato, A., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228529 · Cited by 118
“In the first-line setting, axitinib is approved in combination with pembrolizumab based on the results of the MK426 trial [260] or with avelumab based on the results of the JAVELIN Renal 100 trial [261] Cabozantinib is able to inhibit c-MET, VEGFR2, RET, TRKA, TRKB and Axl.”
BackgroundThe impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 106
Ornstein, M. C., Pal, S. K., Wood, L. S., Tomer, J. M., Hobbs, B. P., Jia, X. S., Allman, K. D., Martin, A. M., Olencki, T. E., Davis, N. B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30513-3 · Cited by 100
Self-citationGul, A., Stewart, T. F., Mantia, C. M., Shah, N. J., Gatof, E. S., Long, Y., Allman, K. D., Ornstein, M. C., Hammers, H. J., McDermott, D. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03315 · Cited by 98
“Ipilimumab and nivolumab have been evaluated in previously treated patients with metastatic RCC.9 Approximately one third of the patients enrolled in CheckMate 016 had prior treatment with cytokines, and 19% had prior VEGF receptor inhibitor treatment, but none of the patients had prior exposure to ICIs.”
BackgroundInfluentialSelf-citationResistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs
Montemagno, C., & Pagès, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00584 · Cited by 104
Bosma, N. A., Warkentin, M. T., Gan, C. L., Karim, S., Heng, D. Y. C., Brenner, D. R., & Lee‐Ying, R. M. (2022) · European Urology Open Science · doi:10.1016/j.euros.2021.12.007 · Cited by 107
“64) Keynote 426 [16,32] Pembro + axitinib 432 138 (32) 238 (55) 56 (13) 71 62 (30-89) 30.”
Mahaki, H., Nobari, S., Tanzadehpanah, H., Babaeizad, A., Kazemzadeh, G., Mehrabzadeh, M., Valipour, A., Yazdinezhad, N., Manoochehri, H., Yang, P., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118023 · Cited by 112
Jia, X., Xu, H., Geng, L., Jiao, M., Wang, W., Jiang, L., & Guo, H. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.001 · Cited by 110
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Adashek, J. J., Subbiah, V., & Kurzrock, R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.009 · Cited by 103
Wu, Z., Chen, Q., Qu, L., Li, M., Wang, L., Mir, M. C., Carbonara, U., Pandolfo, S. D., Black, P. C., Paul, A. K. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.01.028 · Cited by 103
Clear Cell Renal Cell Carcinoma: From Biology to Treatment
Kase, A. M., George, D. J., & Ramalingam, S. (2023) · Cancers · doi:10.3390/cancers15030665 · Cited by 109
“Pembrolizumab plus Axitinib [52,53] PD-1 Phase 3 untreated advanced RCC vs.”
BackgroundMechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 116
“317 Inspiringly, the combination of pembrolizumab or avelumab (anti-PD-L1 antibody) with another small molecule antiangiogenesis agent axitinib has been approved for the treatment of patients with advanced RCC due to the encouraging results of KEYNOTE 426 318 and JAVELIN Renal 101 trials.”
ResultImmunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Hirsch, L., Flippot, R., Escudier, B. J., & Albiges, L. K. (2020) · Drugs · doi:10.1007/s40265-020-01327-7 · Cited by 102
“The subsequent phase III trial confirmed the efficacy of the combination of pembrolizumab and axitinib across the IMDC risk groups and regardless of PD-L1 expression [86].”
BackgroundClinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Geraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck-Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J.-E. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 96
Cardiotoxic effects of angiogenesis inhibitors
Dobbin, S. J. H., Petrie, M. C., Myles, R. C., Touyz, R. M., & Lang, N. N. (2021) · Clinical Science · doi:10.1042/cs20200305 · Cited by 100
Wu, S., Xu, Y., Chen, L., Fan, L., Ma, X.-Y., Zhao, S., Song, X.-Q., Hu, X., Yang, W.-T., Chai, W.-J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01536-6 · Cited by 102
Varayathu, H., Sarathy, V., Thomas, B. E., Mufti, S. S., & Naik, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.559161 · Cited by 104
Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 114
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 106
“While a significant fraction of FOXA1 mutations in cancer are C-terminal truncation mutations (29, 30), we demonstrated that different from the SBR-deficient mutant FOXA1 (1-247), the two PCa-associated C-terminal truncation mutants FOXA1 (1-290) and FOXA1 (1-268) (29, 30) remained the ability to bind to STAT2 and sup…”
BackgroundResultPanowski, S. H., Srinivasan, S., Tan, N., Tacheva-Grigorova, S. K., Smith, B., Mak, Y. S. L., Ning, H., Villanueva, J., Wijewarnasuriya, D., Lang, S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2931 · Cited by 98
“therapies for RCC, including PD-1-targeting agents and combinations, show promising initial response, but low CR (complete remission) rates of 6-16%, highlighting the need for additional treatment options (1-6).”
BackgroundPD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
Zhang, J., Yan, Y., Li, J., Adhikari, R., & Fu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00722 · Cited by 101
“In addition, among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer OS and PFS, as well as a higher ORR, than treatment with sunitinib (Clinical Trials: NCT02853331) (Rini et al., 2019).”
ResultWalsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 100
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 99
Ding, D., Hu, H., Li, S., Zhu, Y., Shi, Y., Liao, M., Liu, J., Tian, X., Liu, A., & Huang, J. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7796 · Cited by 102
Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence
Peired, A. J., Campi, R., Angelotti, M. L., Antonelli, G., Conte, C., Lazzeri, E., Becherucci, F., Calistri, L., Serni, S., & Romagnani, P. (2021) · Cancers · doi:10.3390/cancers13184588 · Cited by 107
Lipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
Rizzo, A., Mollica, V., Santoni, M., Ricci, A. D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., & Massari, F. (2022) · European Urology Focus · doi:10.1016/j.euf.2021.03.001 · Cited by 91
Treatment strategies for clear cell renal cell carcinoma: Past, present and future
Yang, J., Wang, K., & Yang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1133832 · Cited by 107
Yan, X. Q., Ye, M., Zou, Q., Chen, P., He, Z. S., Wu, B., He, D., He, C. H., Xue, X., Ji, Z., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3108 · Cited by 105
Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
Psimaras, D., Velasco, R., Birzu, C., Tamburin, S., Lustberg, M. B., Bruna, J., & Argyriou, A. A. (2019) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12339 · Cited by 102
Dudani, S., Graham, J., Wells, J. C., Bakouny, Z., Pal, S. K., Dizman, N., Donskov, F. N., Porta, C., de Velasco, G., Hansen, A. R., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.048 · Cited by 90
Kim, J., Kim, B., Kang, S. Y., Heo, Y. J., Park, S. H., Kim, S. T., Kang, W. K., Lee, J., & Kim, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00314 · Cited by 98
Mechanisms of angiogenesis in tumour
Zhang, R., Yao, Y., Gao, H., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1359069 · Cited by 109
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 92
“The phase III trial, Keynote 426 (NCT02853331), compared pembrolizumab plus axitinib combination versus sunitinib in first line treatment and showed similar results [47].”
ResultHahn, A. W., Klaassen, Z. W. A., Agarwal, N., Haaland, B. A., Esther, J., Ye, X. Y., Wang, X., Pal, S. K., & Wallis, C. J. D. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.09.002 · Cited by 93
Incorvaia, L., Fanale, D., Badalamenti, G., Porta, C., Olive, D., Luca, I. D., Brando, C., Rizzo, M., Messina, C. G. M., Rediti, M., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1832348 · Cited by 93
“Ongoing clinical trials and others recently concluded continue to study the efficacy of novel drug combinations, with special reference to the anti-PD-L1 agent avelumab or the anti-PD-1 antibody pembrolizumab with the VEGFR-inhibitor axitinib.(19,20) However, although a clinically relevant median response duration is…”
BackgroundGleeson, J. P., Nikolovski, I., DiNatale, R. G., Zucker, M. R., Knežević, A., Patil, S., Ged, Y. M. A., Kotecha, R. R., Shapnik, N., Murray, S. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4367 · Cited by 92
Meng, X., Wu, T., Hong, Y., Fan, Q., Ren, Z., Guo, Y., Yang, X., Shi, P., Yang, J., Yin, X., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00378-2 · Cited by 94
Alaiwi, S. A., Xie, W., Nassar, A. H., Dudani, S., Martini, D. J., Bakouny, Z., Steinharter, J. A., Nuzzo, P. V., Flippot, R., Chanzá, N. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000144 · Cited by 96
Immune checkpoint inhibitors for cancer and venous thromboembolic events
Gong, J., Drobni, Z. D., Alvi, R. M., Murphy, S., Sullivan, R. J., Hartmann, S. E., Gilman, H. K., Lee, H., Zubiri, L., Raghu, V. K., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.010 · Cited by 90
VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications
Camarda, N. D., Travers, R. J., Yang, V. K., London, C. A., & Jaffe, I. Z. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01224-0 · Cited by 95
Figlin, R. A., Tannir, N. M., Uzzo, R. G., Tykodi, S. S., Chen, D. Y. T., Master, V. A., Kapoor, A., Vaena, D. A., Lowrance, W. T., Bratslavsky, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2427 · Cited by 91
“Moreover, the treatment options for patients with previously untreated advanced RCC is continually evolving with promising results from trials employing combination of pembrolizumab plus axitinib (26) or nivolumab plus ipilimumab (8) in the first-line setting.”
BackgroundThe Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
“Pembrolizumab, a humanized IgG4k anti-PD-1 monoclonal antibody marketed as Keytruda® by Merck, later received expanded approval for the treatment of various cancers including cervical cancer (15), endometrial carcinoma (65), esophageal cancer (26), gastric cancer (18), urothelial cancer (19), Hodgkin’s lymphoma (16),…”
BackgroundFirst and Second-line Treatments in Metastatic Renal Cell Carcinoma
Barragán-Carrillo, R., Saad, E., Saliby, R. M., Sun, M., Albiges, L. K., Bex, A., Heng, D. Y. C., Méjean, A., Motzer, R. J., Plimack, E. R., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.10.019 · Cited by 101
Self-citationTumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
Hu, J., Tan, P., Ishihara, M., Bayley, N. A., Schokrpur, S., Reynoso, J. G., Zhang, Y., Lim, R. J., Dumitras, C., Yang, L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01362-2 · Cited by 85
Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
Peranzoni, E., Ingangi, V., Masetto, E., Pinton, L., & Marigo, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01590 · Cited by 86
Terry, S., Dalban, C., Rioux-Leclercq, N. C., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0972 · Cited by 100
Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2275 · Cited by 79
“In the renal cell carcinoma trials KEYNOTE-426 (35) and JAVELIN Renal 101 ( Fig.”
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 89
“1 months) for pembrolizumab plus axitinib therapy with respect to sunitinib monotherapy [124].”
BackgroundCarretero-González, A., Lora, D., Martín-Sobrino, I., Sanz, I. S., Bourlon, M. T., Herranz, U. A., Chanzá, N. M., Castellano, D., & de Velasco, G. (2020) · Cancers · doi:10.3390/cancers12071945 · Cited by 92
“On the other side, in the phase 3 KEYNOTE-426 trial, treatment with pembrolizumab plus axitinib resulted in longer OS and PFS compared to sunitinib and regardless of PD-L1 expression measured by CPS (tumor and immune cells); however there was a trend of a greater benefit in patients with higher PD-L1 expression [5].”
ResultHashimoto, K. (2021) · Cancers · doi:10.3390/cancers13102288 · Cited by 88
A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma
Alchahin, A. M., Mei, S., Τσέα, Ι., Hirz, T., Kfoury, Y. S., Dahl, D. M., Wu, C., Subtelny, A. O., Wu, S., Scadden, D. T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33375-w · Cited by 93
Santoni, M., Buti, S., Myint, Z. W., Maruzzo, M., Iacovelli, R., Pichler, M., Kopecký, J., Kucharz, J., Rizzo, M., Galli, L., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.07.003 · Cited by 94
Liu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 87
Fighting in a wasteland: deleterious metabolites and antitumor immunity
Watson, M. J., & Delgoffe, G. M. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148549 · Cited by 86
“Patients with previously untreated metastatic RCC were given pembrolizumab and axitinib (VEGFR1, VEGFR2, and VEGFR3 inhibitor) combination therapy, which statistically improved progression-free survival over sunitinib monotherapy, leading to FDA approval for treatment-naive RCC patients (137).”
BackgroundModulation of RNA splicing enhances response to BCL2 inhibition in leukemia
Wang, E., Pineda, J. M. B., Kim, W. J., Chen, S., Bourcier, J., Stahl, M. F., Hogg, S. J., Bewersdorf, J. P., Han, C., Singer, M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.12.002 · Cited by 97
“Combinatorial therapies have been widely used to circumvent acquired drug resistance and as an approach with proven clinical efficacy for the treatment of several cancer types.(19,20) In AML, the combination of venetoclax with hypomethylating agents is now widely used and has significantly improved the response and su…”
BackgroundMetabolic reprogramming of clear cell renal cell carcinoma
Zhu, H., Wang, X., Lu, S., & Ou, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1195500 · Cited by 94
“Evidence suggests that these therapies can extend the overall and progression-free survival of patients, but they are also associated with the occurrence of adverse events (10, 11).”
BackgroundClinical implications of food–drug interactions with small-molecule kinase inhibitors
Veerman, G., Hussaarts, K. G. A. M., Jansman, F. G. A., Koolen, S. L. W., van Leeuwen, R. W. F., & Mathijssen, R. H. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30069-3 · Cited by 89
Nakajima, T. E., Kadowaki, S., Minashi, K., Nishina, T., Yamanaka, T., Hayashi, Y., Izawa, N., Muro, K., Hironaka, S., Kajiwara, T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3559 · Cited by 82
Renal cell carcinoma therapy: Current and new drug candidates
Pontes, O., Oliveira-Pinto, S., Baltazar, F., & Costa, M. F. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.009 · Cited by 85
Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer
Hannan, R., Christensen, M., Hammers, H. J., Christie, A. L., Paulman, B., Lin, D., Garant, A., Arafat, W., Courtney, K. D., Bowman, I. A., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2021.12.001 · Cited by 82
“1 mo for pembrolizumab/axitinib [3], 13.”
Ernst, M. S., Navani, V., Wells, J. C., Donskov, F. N., Basappa, N. S., Labaki, C., Pal, S. K., Meza, L., Wood, L. A., Ernst, D. S., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.01.001 · Cited by 82
Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Gao, F., & Yang, C. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666191114110359 · Cited by 86
Massari, F., Mollica, V., Rizzo, A., Cosmai, L., Rizzo, M., & Porta, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1811226 · Cited by 81
“patients with previously untreated metastatic RCC, treatment with pembrolizumab plus axitinib resulted in significantly longer OS and progression-free survival (PFS), as well as a higher objective response rate (ORR), than sunitinib monotherapy, irrespective of the IMDC risk stratification [9].”
BackgroundMethodInfluentialFumet, J.-D., Limagne, E., Thibaudin, M., & Ghiringhelli, F. (2020) · Cancers · doi:10.3390/cancers12092637 · Cited by 85
“In urological cancer, a combination of gemcitabine and platinum or anthracycline with platinum (like in the MVAC regimen) may be of interest for urothelial cancer, while targeted therapies are probably the best partner to be combined with immune checkpoint inhibitors for renal carcinoma [86].”
BackgroundMolecular Pathology of Lung Cancer
Saller, J. J., & Boyle, T. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037812 · Cited by 99
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Bansal, D., Reimers, M. A., Knoche, E. M., & Pachynski, R. K. (2021) · Cancers · doi:10.3390/cancers13020334 · Cited by 85
“The combination of TKI and CPI has already shown synergy and has been approved in NSCLC and renal cell carcinoma (RCC) [157,158].”
BackgroundRenal Cell Carcinoma and Kidney Transplantation: A Narrative Review
Dahle, D. O., Skauby, M., Langberg, C. W., Brabrand, K., Wessel, N., & Midtvedt, K. (2021) · Transplantation · doi:10.1097/tp.0000000000003762 · Cited by 83
Riaz, I. B., He, H., Ryu, A. J., Siddiqi, R. L., Naqvi, S. A. A., Yao, Y., Husnain, M., Narasimhulu, D. M., Mathew, J., Sipra, Q. U. A. R., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.016 · Cited by 86
Li, S., Chen, J. Y., & Sun, Z. (2021) · 癌症:英文版 · doi:10.1002/cac2.12183 · Cited by 87
“0001) in comparison with standard-of-care sunitinib in RCC [93].”
ResultInfluentialUpdates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma
Kim, M., Jin, Z., Kolb, R. H., Borcherding, N. C., Chatzkel, J. A., Falzarano, S. M., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13225856 · Cited by 88
“In an open-label phase III trial (Keynote 426), 861 patients with previously untreated advanced ccRCC were assigned to either axitinib plus pembrolizumab (anti-PD-1) or sunitinib alone group [25,97,98].”
Background
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.